Study summary

An all-pill treatment put most older patients into remission

All-oral AML trial · Phase 1-2, single-arm · Published June 2026, New England Journal of Medicine

What was tested

Oral decitabine-cedazuridine plus oral venetoclax, with no infusions, for newly diagnosed AML in people 75 or older or unable to have intensive chemotherapy.

What they found

• 47% had a complete response, and 63% a complete response or complete response with incomplete blood count recovery.
• Mortality was 3% at 30 days and 10% at 60 days.

What it means

Could let many older patients be treated largely at home rather than with clinic infusions.